News | November 10, 2021
Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The company has operations in North America, Asia, and Europe,
Expertise in exosomes isolation and characterization will drive innovation in this field
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Gini Health works in the domain of personalised healthcare
The combined entity will have 12 hospitals with 3,666 beds
It is the first integrated digital PCR solution ideal for oncology, cell and gene therapy development
Dr Lal PathLabs revenue contribution from west India to go up from 10% to 24% post-acquisition basis FY21
This strategic collaboration will enable continued innovation in cancer care
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
